Clinical application of hyperthermia combined with anticancer drugs for the treatment of solid tumors.

BACKGROUND Hyperthermia is one of the modalities used to treat various forms of malignancies, including esophageal, stomach, or rectal cancers. METHODS The basic mechanism of synergism between hyperthermia and anticancer drugs, as well as the clinical result of hyperthermia for the treatment of gastrointestinal malignancy, was reviewed. RESULTS Hyperthermia exerts a cytotoxic effect in combination with various mechanisms. Hyperthermia is applied in combination with chemotherapy and/or radiotherapy in the clinical setting. Among the anticancer drugs that are synergistic with hyperthermia is cisplatin, which is prevalent for clinical application. The mechanism of enhanced cytotoxicity of cisplatin includes increased intracellular drug accumulation, increased platinum-DNA adducts, and inhibition of DNA repair. At our institute, hyperthermochemoradiotherapy was conducted as a neoadjuvant therapy for either operative cases or as a palliative therapy for unresectable cases for esophageal and rectal cancers. In both situations, hyperthermochemoradiotherapy showed an excellent benefit in both the control of local recurrence and and in an improvement in patient survival. Regarding gastric cancer, the most popular application of hyperthermia was the intraoperative hyperthermic peritoneal lavage with cisplatin. This treatment modality demonstrated a better control of the disseminated lesion. Regarding the factors that influence thermosensitivity, in vitro experiments demonstrated the heat-shock proteins or tumor suppressor gene p53 to be related to thermosensitivity. In the clinical setting, these factors remain to be firmly established as predictive factors for thermosensitivity. CONCLUSIONS It is evident that hyperthermia was effective in the control of far-advanced gastrointestinal malignancies. When more reliable factors for the prediction of the treatment response can be established, the standard guidelines for the application of hyperthermia can then be made.

[1]  J. Bull,et al.  Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells , 1994, Cancer Chemotherapy and Pharmacology.

[2]  M. Itoh,et al.  Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer , 1993, Surgery Today.

[3]  Y. Maehara,et al.  Heat enhances the cytotoxicity ofcis-diamminedichloroplatinum(II) and its analoguescis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4-butanediammineplatinum(II) andcis-diammine(glycolato)platinum in vitro , 2004, Cancer Chemotherapy and Pharmacology.

[4]  Y. Maehara,et al.  Increased cytotoxicity of low-dose, long-duration exposure to 5-fluorouracil of V-79 cells with hyperthermia , 2004, Cancer Chemotherapy and Pharmacology.

[5]  P M Schlag,et al.  Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters. , 2000, International journal of radiation oncology, biology, physics.

[6]  A. Takahashi,et al.  Transfection with mutant p53 gene inhibits heat-induced apoptosis in a head and neck cell line of human squamous cell carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[7]  Y. Maehara,et al.  Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. , 2000, Hepato-gastroenterology.

[8]  P. Sugarbaker,et al.  Clinical Pathway for the Management of Resectable Gastric Cancer with Peritoneal Seeding: Best Palliation with a Ray of Hope for Cure , 2000, Oncology.

[9]  J. Haveman,et al.  Inactivation of p53 and of pRb protects human colorectal carcinoma cells against hyperthermia-induced cytotoxicity and apoptosis , 1999, Journal of Cancer Research and Clinical Oncology.

[10]  K. Hirose,et al.  Efficacy of Continuous Hyperthermic Peritoneal Perfusion for the Prophylaxis and Treatment of Peritoneal Metastasis of Advanced Gastric Cancer: Evaluation by Multivariate Regression Analysis , 1999, Oncology.

[11]  S. Frede,et al.  Role of Tumor Necrosis Factor α in Hyperthermia-induced Apoptosis of Human Leukemia Cells , 1999 .

[12]  P. Wust,et al.  Preoperative treatment of rectal cancer with radiation, chemotherapy and hyperthermia: analysis of treatment efficacy and heat-shock response. , 1999, Radiation research.

[13]  S. Fujimoto,et al.  Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma , 1999, Cancer.

[14]  S. Fushida,et al.  A new surgical approach (peritonectomy) for the treatment of peritoneal dissemination. , 1999, Hepato-gastroenterology.

[15]  M. Turman,et al.  Heat shock protein 70 overexpression protects LLC-PK1 tubular cells from heat shock but not hypoxia. , 1999, Kidney international.

[16]  T. Ishikawa,et al.  Continuous hyperthermic peritoneal perfusion for peritoneal dissemination of gastric cancer. , 1998, Hepato-gastroenterology.

[17]  C. Ng,et al.  Concomitant treatment with mild hyperthermia, cisplatin and low dose-rate irradiation in human ovarian cancer cells sensitive and resistant to cisplatin. , 1998, Oncology reports.

[18]  C. Christophi,et al.  The treatment of malignancy by hyperthermia. , 1998, Surgical oncology.

[19]  F. Bozzetti,et al.  Intraperitoneal Hyperthermic Chemotherapy in Gastric Cancer: Rationale for a new Approach , 1998, Tumori.

[20]  H. Park,et al.  Apoptosis and perturbation of cell cycle progression in an acidic environment after hyperthermia. , 1998, Cancer research.

[21]  R. Higashikubo,et al.  Intracellular distribution of hsp70 during long duration moderate hyperthermia. , 1998, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[22]  H. Bartelink,et al.  Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. , 1998, European journal of cancer.

[23]  J. Inazawa,et al.  Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers. , 1998, British Journal of Cancer.

[24]  P. Mirkes.  Molecular/cellular biology of the heat stress response and its role in agent-induced teratogenesis. , 1997, Mutation research.

[25]  L. Bourget,et al.  Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis , 1997, Molecular and cellular biology.

[26]  A. Takahashi,et al.  Transfection of p53-knockout mouse fibroblasts with wild-type p53 increases the thermosensitivity and stimulates apoptosis induced by heat stress. , 1997, International journal of radiation oncology, biology, physics.

[27]  H. Kampinga,et al.  Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. , 1997, British Journal of Cancer.

[28]  Y. Maehara,et al.  Improved surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patients with carcinoma of the rectum , 1997, Diseases of the colon and rectum.

[29]  S. Fujimoto,et al.  Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery , 1997, Cancer.

[30]  M. Martel,et al.  125 Radiation pneumonitis as a function of dose and volume; An analysis of pooled data of 442 patients , 1997 .

[31]  J. Inazawa,et al.  p53 gene mutation is not directly related to tumoricidal effects of preoperative radiochemohyperthermia therapy for rectal cancers , 1996, Journal of surgical oncology.

[32]  Peter A. Hall,et al.  EDITORIAL. p53—INTEGRATING THE COMPLEXITY , 1996 .

[33]  Y. Maehara,et al.  Recurrences and related characteristics of gastric cancer. , 1996, British Journal of Cancer.

[34]  K. Engin.  Biological rationale and clinical experience with hyperthermia. , 1996, Controlled clinical trials.

[35]  D. Ichikawa,et al.  Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia, and 5-fluorouracil suppository. , 1996, American journal of surgery.

[36]  F. Liu,et al.  Potential role of HSP70 as an indicator of response to radiation and hyperthermia treatments for recurrent breast cancer. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[37]  M. Jäättelä,et al.  HSP27 and HSP70 increase the survival of WEHI-S cells exposed to hyperthermia. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[38]  K. Sugimachi,et al.  Hyperthermia combined with chemotherapy and irradiation for the prolongation of the postoperative prognosis in the patients with esophageal carcinoma invading neighbouring structures. , 1996, International surgery.

[39]  V. Bertone,et al.  Lysosomal exocytosis induced by hyperthermia: a new model of cancer death. III. Effect on liver metastasis. , 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[40]  H. Ito,et al.  Regional differences in apoptosis in murine gliosarcoma (T9) induced by mild hyperthermia. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[41]  M. Yasuda,et al.  Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal carcinoma , 1995, Journal of surgical oncology.

[42]  D. Latchman,et al.  Stable high level expression of a transfected human HSP70 gene protects a heart-derived muscle cell line against thermal stress. , 1994, Journal of molecular and cellular cardiology.

[43]  M. Kerstein,et al.  Prediction of outcome in “Resectable” esophageal carcinoma , 1993, Journal of surgical oncology.

[44]  Z. Darżynkiewicz,et al.  The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. , 1993, Cancer research.

[45]  Y. Gao,et al.  Combination preoperative radiation and endocavitary hyperthermia for rectal cancer: long-term results of 44 patients. , 1993, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[46]  Y. Maehara,et al.  Hyperthermia enhances the inhibition of tumor growth by 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil/uracil (1:4) in tumors in mice and humans , 1992, Cancer.

[47]  G. Steele,et al.  Patterns of recurrent colorectal cancer and recovery surgery , 1992, Cancer.

[48]  M. Morita,et al.  Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus--a prospective randomized trial. , 1992, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[49]  J. Bull,et al.  Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. , 1991, Cancer research.

[50]  C. Winterford,et al.  The role of apoptosis in the response of cells and tumours to mild hyperthermia. , 1991, International journal of radiation biology.

[51]  P. Sminia,et al.  Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. , 1991, European journal of cancer.

[52]  S. Fushida,et al.  Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second‐look operation , 1990, Cancer.

[53]  G. Hahn,et al.  Biochemical analysis of heat-resistant mouse tumor cell strains: a new member of the HSP70 family , 1989, Molecular and cellular biology.

[54]  N. Hornback,et al.  Historical aspects of hyperthermia in cancer therapy. , 1989, Radiologic clinics of North America.

[55]  K. Sugimachi,et al.  Preoperative hyperthermochemoradiotherapy for patients with rectal cancer , 1989, Diseases of the colon and rectum.

[56]  K. Sugimachi,et al.  Long-term effects of hyperthermia combined with chemotherapy and irradiation for the treatment of patients with carcinoma of the esophagus. , 1988, Surgery, gynecology & obstetrics.

[57]  K. Sugimachi,et al.  Preoperative hyperthermia combined with radiotherapy and chemotherapy for patients with incompletely resected carcinoma of the esophagus , 1988, Cancer.

[58]  I. Krakoff.  The Development of More Effective Platinum Therapy , 1988 .

[59]  K. Wallner,et al.  Effect of drug exposure duration and sequencing on hyperthermic potentiation of mitomycin-C and cisplatin. , 1987, Cancer research.

[60]  K. Wallner,et al.  Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. , 1986, Cancer research.

[61]  W. Mackillop,et al.  Hyperthermia, adriamycin transport, and cytotoxicity in drug-sensitive and -resistant Chinese hamster ovary cells. , 1986, Cancer research.

[62]  K. Sugimachi,et al.  Histopathological evaluation of hyperthermochemo radiotherapy for carcinoma of the esophagus , 1986, Journal of surgical oncology.

[63]  E. Hughes,et al.  Local recurrence after potentially curative resection for rectal cancer in a series of 1008 patients , 1985, The British journal of surgery.

[64]  W. Dewey,et al.  Effect of hyperthermia on CHO DNA polymerases alpha and beta. , 2010, Radiation research.

[65]  W. Dewey,et al.  Inhibition of replicon initiation and DNA elongation in Chinese hamster ovary cells by treatment at 45. 5 degrees C , 1982 .

[66]  R. Meyn,et al.  Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). , 1980, Cancer research.

[67]  K. Kohn,et al.  Mechanism of action of cis-dichlorodiammineplatinum(II). , 1979, Cancer treatment reports.

[68]  G. Hahn.  Potential for therapy of drugs and hyperthermia. , 1979, Cancer research.

[69]  C. Crifó,et al.  The biochemical mechanism of selective heat sensitivity of cancer cells. IV. Inhibition of RNA synthesis. , 1973, European journal of cancer.